— Main Menu —
HOME
DCVAX ® TECHNOLOGY
- About DCVax®
- Dendritic Cell Immunotherapy
- Patient Stories & Physician Comments
PRODUCT CANDIDATES
- DCVax® – L
- DCVax® – Direct
- DCVax® – Prostate
CLINICAL TRIALS
- DCVax® – L Phase III for GBM Brain Cancer
- DCVax® – Direct Phase I/II for All Types of Inoperable Solid Tumor Cancers
INVESTORS & MEDIA
- Press Releases
- SEC Filings
- Webcasts
- Board Committee Charters
- Code of Conduct
- Notice of Proposed Settlement
- Related-Party Transaction Policy
- Corporate Governance Guidelines
ABOUT US
- Overview
- Company Management
- Publications
- Related Links
- Contact Us
- - General Inquiries
- - New Patient Inquiry
HOME
DCVAX ® TECHNOLOGY
About DCVax®
Dendritic Cell Immunotherapy
Patient Stories & Physician Comments
PRODUCT CANDIDATES
DCVax® – L
DCVax® – Direct
DCVax® – Prostate
CLINICAL TRIALS
DCVax® – L Phase III for GBM Brain Cancer
DCVax® – Direct Phase I/II for All Types of Inoperable Solid Tumor Cancers
INVESTORS & MEDIA
Press Releases
SEC Filings
Webcasts
Board Committee Charters
Code of Conduct
Notice of Proposed Settlement
Related-Party Transaction Policy
Corporate Governance Guidelines
ABOUT US
Overview
Company Management
Publications
Related Links
Contact Us
General Inquiries
New Patient Inquiry
Notice of Proposed Settlement
Stipulation of Settlement.pdf
Notice of Settlement.pdf